1. @entity1812 promotes @entity528 and @entity2657 through the activation of the B(2) receptor. The neuroprotective effect of LF 16-0687 Ms, a B(2) receptor antagonist, has been described when given prior to induction of transient focal @entity2806 in @entity35 , but there are no data regarding the consequence of a treatment when given after injury. Therefore, in a @entity19 model of transient @entity2500 ( @entity2500 ), we evaluated the effect of LF 16-0687 Ms given prior to and/or after the onset of @entity63 on @entity51 , @entity1188 volume and inflammatory responses including @entity2657 , blood-brain barrier (BBB) disruption and neutrophil accumulation. 2. LF 16-0687 Ms (1, 2 and 4 mg kg(-1)) administered 0.5 h before and, 1.25 and 6 h after @entity2500 , decreased the @entity1188 volume by a maximum of 33% and significantly improved the neurological recovery. 3. When given at 0.25 and 6.25 h after @entity2500 , LF 16-0687 Ms (1.5, 3 and 6 mg kg(-1)) decreased the @entity1188 volume by a maximum of 25% and improved the neurological score. 4. Post-treatment with LF 16-0687 Ms (1.5 mg kg(-1)) significantly decreased @entity2657 (-28%), BBB disruption (-60%) and neutrophil accumulation (-65%) induced by @entity63 . Physiological parameters were not modified by LF 16-0687 Ms. 5. These data emphasize the role of @entity1812 B(2) receptor in the development of @entity4798 , @entity51 and inflammatory responses resulting from transient focal @entity2806 . Therefore, B(2) receptor antagonist might represent a new therapeutic approach in the pharmacological treatment of @entity64 .

LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces @entity2806 in a XXXX model of transient focal @entity2806 .

@entity4798 :: ('MESH:D020520', 'Disease') :: ['infarct lesion'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity2657 :: ('MESH:D001929', 'Disease') :: ['cerebral edema', 'brain edema'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia'] @entity19 :: ('10090', 'Species') :: ['murine'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['middle cerebral artery occlusion', 'MCAO'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity1812 :: ('MESH:D001920', 'Chemical') :: ['Bradykinin', 'bradykinin'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal damage']
@entity19 :: (10090,Species) :: ['murine']
